Anaplastic glioma: Standards and new developments in diagnostics and therapy

被引：0

作者：

Wick W. ^{[1
,5
]}

Von Deimling A. ^{[2
]}

Grabenbauer G.G. ^{[3
]}

Westphal M. ^{[4
]}

机构：

[1] Zentrum Neurologie, Universität Tübingen

[2] Institut für Neuropathologie, Charité, Universitätsmedizin Berlin

[3] Strahlenklinik, Universität Erlangen-Nürnberg

[4] Neurochirurgische Klinik, Universitätsklinikums Hamburg Eppendorf

[5] Zentrum Neurologie, Universität Tübingen, 72076 Tübingen

来源：

Der Onkologe | 2006年 / 12卷 / 6期

关键词：

Anaplastic gliomas; LOH; 1p/19q; Molecular diagnostics; Radiochemotherapy; Temozolomide;

D O I：

10.1007/s00761-006-1068-9

中图分类号：

学科分类号：

摘要：

Recent developments in molecular diagnostics, especially the determination of a beneficial impact of the loss of heterozygosity (LOH) on chromosomes 1p and 19q, are influencing scientific and clinical studies on anaplastic glioma. Results from the new EORTC 26951 and RTOG 9402 studies imply the differentiation of tumors with and without LOH 1p/19q in the near future. This review discusses the state of the art in imaging, surgery, and the radio- as well as chemotherapy of anaplastic gliomas. Future concepts for an evaluation of radiochemotherapy with temozolomide for anaplastic gliomas without LOH 1p/19q, and analysis of the relevance of this combined modality treatment on overall survival, are outlined. The therapeutic challenge for anaplastic gliomas with a better prognosis (with LOH 1p/19q) is the identification of an experimental study arm that allows a prolongation of overall and not just progression-free survival in this patient cohort. © Springer Medizin Verlag 2006.

引用

页码：508 / 517

页数：9

共 36 条

[21]

Oppitz U., Maessen D., Zunterer H., Et al., 3d-recurrence-patterns of glioblastomas after CT-planned postoperative irradiation, Radiother Oncol, 53, pp. 53-57, (1999)

[22]

Popperl G., Goldbrunner R., Gildehaus F.J., Et al., O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma, Eur J Nucl Med Mol Imaging, 32, pp. 1018-1025, (2005)

[23]

Shapiro W.R., Green S.B., Burger P.C., Et al., Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma, J Neurosurg, 71, pp. 1-9, (1989)

[24]

Stupp R., Mason W.P., Van Den Bent M.J., Et al., Radiotherapy plus concomitant and adjuvant temozolomide for patients with newly diagnosed glioblastoma, N Engl J Med, 352, pp. 987-996, (2005)

[25]

Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: A Medical Research Council trial, J Clin Oncol, 19, pp. 509-518, (2001)

[26]

Van Den Bent M.J., Chinot O., Boogerd W., Et al., Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972, Ann Oncol, 14, pp. 599-602, (2003)

[27]

Van Den Bent M.J., Delattre J., Brandes A.A., Et al., First analysis of EORTC trial 26951, a randomized phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendroglioma, J Clin Oncol, 23, (2005)

[28]

Van Den Bent M.J., Taphoorn M.J., Brandes A.A., Et al., Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971, J Clin Oncol, 21, pp. 2525-2528, (2003)

[29]

Vuorinen V., Hinkka S., Farkkila M., Et al., Debulking or biopsy of malignant glioma in elderly people - A randomized study, Acta Neurochir, 145, pp. 5-10, (2003)

[30]

Walker M.D., Alexander E., Hunt W.E., Et al., Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial, J Neurosurg, 49, pp. 333-343, (1978)

← 1 2 3 4 →